报价延迟最少15分钟:2026/03/09 10:57 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.97 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.83/-3.32
|
|
企业价值
851.59M
|
| 资产负债 |
|
每股账面净值
15.73
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
10.00M
|
|
每股收益
0.14
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. |
